title: Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis.
abstract: BACKGROUND
  Leukotriene-receptor antagonists (LTRAs) are recommended as an alternative treatment in patients with mild asthma, but their effect compared with placebo is unclear.
  
  
  OBJECTIVE
  To determine the benefits and harms of LTRAs as monotherapy or in combination with inhaled corticosteroids compared with placebo in adults and adolescents with asthma.
  
  
  METHODS
  MEDLINE and the Cochrane Central Register of Controlled Trials from inception through June 2015.
  
  
  METHODS
  Peer-reviewed, English-language, randomized, controlled trials in patients with asthma that reported the effect of LTRAs versus placebo on measures of asthma control.
  
  
  METHODS
  Three researchers extracted data on study population, interventions, outcome measures, and adverse events. One researcher assessed risk of bias.
  
  
  RESULTS
  Of the 2008 abstracts that were screened, 50 trials met eligibility criteria. Random-effects meta-analyses of 6 trials of LTRA monotherapy showed that LTRAs reduced the risk for an exacerbation (summary risk ratio [RR], 0.60 [95% CI, 0.44 to 0.81]). In 4 trials of LTRAs as add-on therapy to inhaled corticosteroids, the summary RR for exacerbation was 0.80 (CI, 0.60 to 1.07). Leukotriene-receptor antagonists either as monotherapy or as add-on therapy to inhaled corticosteroids increased FEV1, whereas FEV1 percentage of predicted values was improved only in trials of LTRA monotherapy. Adverse event rates were similar in the intervention and comparator groups.
  
  
  CONCLUSIONS
  Variation in definitions and reporting of outcomes, high risk of bias in some studies, heterogeneity of findings, possible selective outcome reporting bias, and inability to assess the effect of asthma severity on summary estimates.
  
  
  CONCLUSIONS
  Leukotriene-receptor antagonists as monotherapy improved asthma control compared with placebo, but which patients are most likely to respond to treatment with LTRAs remains unclear.
  
  
  BACKGROUND
  National Institutes of Health.
authors.forename: Michael
authors.initials: M
authors.lastname: Miligkos
authors.forename: Raveendhara R
authors.initials: RR
authors.lastname: Bannuru
authors.forename: Hadeel
authors.initials: H
authors.lastname: Alkofide
authors.forename: Sucharita R
authors.initials: SR
authors.lastname: Kher
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Schmid
authors.forename: Ethan M
authors.initials: EM
authors.lastname: Balk
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005541:Forced Expiratory Volume; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D020024:Leukotriene Antagonists